Patient-specific drug-resistant bacterial strain

A patient-specific drug-resistant bacterial strain refers to a unique isolate of a pathogen, such as Methicillin-resistant Staphylococcus aureus (MRSA) or Carbapenem-resistant Enterobacteriaceae (CRE), that has acquired genetic determinants allowing it to survive antimicrobial treatment (CDC, 2022). These strains are not individual molecular targets but are complex biological entities that contain multiple potential drug targets, such as cell wall enzymes or ribosomal proteins (WHO, 2024). In clinical practice, these strains are identified through phenotypic susceptibility testing and genomic sequencing to guide personalized therapy, particularly when standard treatments fail (NIH, 2023). The emergence of these strains is driven by selective pressure from antibiotic use and horizontal gene transfer within healthcare settings. Therapeutic strategies often involve combination therapies or novel approaches like bacteriophage therapy, which utilizes viruses that specifically infect the patient's unique bacterial isolate. Consequently, while the strain is the object of the treatment, the pharmacological targets are the specific molecular components within the strain that the drugs or phages bind to. Understanding the specific resistance profile of a patient's isolate is crucial for selecting effective interventions and preventing the spread of healthcare-associated infections.

Other names

Multidrug-resistant organism (MDRO)SuperbugClinical isolateAntibiotic-resistant bacteriaPatient-specific isolate

Mechanisms of action for drugs addressing these strains include the inhibition of cell wall synthesis, inhibition of protein synthesis, disruption of cell membrane integrity, and inhibition of nucleic acid synthesis (StatPearls, 2023).